Robert M. Jotte

14.2k total citations · 5 hit papers
111 papers, 6.9k citations indexed

About

Robert M. Jotte is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert M. Jotte has authored 111 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 68 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Robert M. Jotte's work include Lung Cancer Treatments and Mutations (61 papers), Cancer Immunotherapy and Biomarkers (41 papers) and Lung Cancer Research Studies (41 papers). Robert M. Jotte is often cited by papers focused on Lung Cancer Treatments and Mutations (61 papers), Cancer Immunotherapy and Biomarkers (41 papers) and Lung Cancer Research Studies (41 papers). Robert M. Jotte collaborates with scholars based in United States, Italy and Germany. Robert M. Jotte's co-authors include Mark A. Socinski, Federico Cappuzzo, Delvys Rodríguez‐Abreu, Daniil Stroyakovskiy, Martin Reck, Fabrice Barlési, Denis Moro‐Sibilot, Francesco Orlandi, Naoyuki Nogami and Anthony Lee and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Robert M. Jotte

106 papers receiving 6.8k citations

Hit Papers

Atezolizumab for First-Line Treatment of Metastatic Nonsq... 2018 2026 2020 2023 2018 2019 2020 2021 2023 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    2018 2.6k citations Mark A. Socinski, Robert M. Jotte et al. profile →
  2. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    2019 688 citations Martin Reck, Tony Mok et al. profile →
  3. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
    2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →
  4. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
    2021 316 citations Mark A. Socinski, Makoto Nishio et al. Journal of Thoracic Oncology profile →
  5. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
    2023 102 citations Mark A. Socinski, Robert M. Jotte et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert M. Jotte United States 31 5.6k 4.0k 1.4k 1.0k 744 111 6.9k
Piotr Serwatowski Germany 15 4.0k 0.7× 3.5k 0.9× 1.0k 0.7× 760 0.7× 626 0.8× 28 5.3k
Martin Sebastian Germany 27 4.1k 0.7× 3.3k 0.8× 1.7k 1.2× 945 0.9× 930 1.3× 117 5.8k
Naoyuki Nogami Japan 30 5.9k 1.0× 5.4k 1.3× 1.4k 1.0× 757 0.7× 969 1.3× 149 7.4k
Aleksandra Szczęsna Poland 23 4.4k 0.8× 4.2k 1.0× 1.2k 0.8× 381 0.4× 665 0.9× 73 5.8k
Shunichi Sugawara Japan 36 4.2k 0.8× 3.5k 0.9× 1.1k 0.8× 448 0.4× 548 0.7× 209 5.4k
Neal Ready United States 36 4.2k 0.8× 2.8k 0.7× 1.1k 0.7× 741 0.7× 481 0.6× 160 5.7k
Melissa L. Johnson United States 42 5.0k 0.9× 3.4k 0.9× 2.3k 1.6× 1.2k 1.1× 1.1k 1.5× 359 7.1k
Shengxiang Ren China 46 4.4k 0.8× 3.8k 0.9× 2.4k 1.7× 1.1k 1.1× 1.8k 2.4× 249 7.3k
Hidetoshi Hayashi Japan 36 3.7k 0.7× 2.8k 0.7× 1.4k 1.0× 488 0.5× 705 0.9× 248 5.2k
Chunxia Su China 36 2.6k 0.5× 2.3k 0.6× 1.3k 0.9× 541 0.5× 996 1.3× 181 4.5k

Countries citing papers authored by Robert M. Jotte

Since Specialization
Citations

This map shows the geographic impact of Robert M. Jotte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Jotte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Jotte more than expected).

Fields of papers citing papers by Robert M. Jotte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Jotte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Jotte. The network helps show where Robert M. Jotte may publish in the future.

Co-authorship network of co-authors of Robert M. Jotte

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Jotte. A scholar is included among the top collaborators of Robert M. Jotte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Jotte. Robert M. Jotte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lu, Tianshi, Habib Hamidi, Mark A. Socinski, et al.. (2025). Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. Nature Communications. 17(1). 122–122.
3.
Butrynski, James E., John C. Paschold, Patrick J. Ward, et al.. (2024). Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.. Journal of Clinical Oncology. 42(16_suppl). 8047–8047. 1 indexed citations
4.
Lu, Shun, Fabrice Barlési, Robert M. Jotte, et al.. (2024). OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12. Journal of Thoracic Oncology. 19(10). S30–S30. 2 indexed citations
5.
Colevas, A. Dimitrios, Christine H. Chung, Douglas R. Adkins, et al.. (2024). A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).. Journal of Clinical Oncology. 42(16_suppl). 6004–6004. 8 indexed citations
6.
Garassino, Marina Chiara, Willemijn S.M.E. Theelen, Robert M. Jotte, et al.. (2023). LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology. 34. S1309–S1310. 37 indexed citations
7.
He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations
8.
9.
Reck, Martin, Tony Mok, Mark A. Socinski, et al.. (2020). 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. Annals of Oncology. 31. S837–S838. 12 indexed citations
10.
Spigel, David R., Robert M. Jotte, John Nemunaitis, et al.. (2020). Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). Journal of Thoracic Oncology. 16(2). 327–333. 36 indexed citations
11.
Stewart, Tracy Murray, Daniel D. Von Hoff, Michael L. Fitzgerald, et al.. (2020). A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology. 87(1). 135–144. 15 indexed citations
12.
Spira, Alexander I., Collin M. Blakely, Kai He, et al.. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology. 29. viii400–viii401. 9 indexed citations
13.
Spigel, David R., Robert M. Jotte, Santiago Ponce Aix, et al.. (2018). nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. Annals of Oncology. 29. viii749–viii750. 1 indexed citations
14.
Langer, Corey J., Edward S. Kim, Eric Anderson, et al.. (2018). nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology. 8. 262–262. 7 indexed citations
15.
Reck, Martin, Mark A. Socinski, Federico Cappuzzo, et al.. (2017). Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150). Annals of Oncology. 28. xi31–xi31. 32 indexed citations
16.
Mok, Tony, Federico Cappuzzo, Robert M. Jotte, et al.. (2015). 356TiP Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC. Annals of Oncology. 26. ix103–ix103. 3 indexed citations
17.
Movsas, Benjamin, Corey J. Langer, Helen J. Ross, et al.. (2010). Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(5). 673–679. 14 indexed citations
18.
Reynolds, Craig H., Robert M. Jotte, Alexander I. Spira, et al.. (2009). Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(12). 1537–1543. 46 indexed citations
19.
20.
Spalding, Aaron C., Robert M. Jotte, Robert I. Scheinman, et al.. (2002). TRAIL and inhibitors of apoptosis are opposing determinants for NF-κB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene. 21(2). 260–271. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Piotr Serwatowski Breakdown of academic impact, for papers by Martin Sebastian Breakdown of academic impact, for papers by Naoyuki Nogami Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Neal Ready Breakdown of academic impact, for papers by Melissa L. Johnson Breakdown of academic impact, for papers by Shengxiang Ren Breakdown of academic impact, for papers by Hidetoshi Hayashi Breakdown of academic impact, for papers by Chunxia Su
Rankless by CCL
2026